Bodycote’s updated narrative reflects a modestly higher fair value of £7.78 per share, even as revenue expectations swing from a previously assumed +13.3% increase to an estimated -8.4% decline. This shift captures a market split between analysts who see resilient medium term earnings power and those who remain cautious about near term demand and execution risks. Stay tuned to see how investors can track these evolving assumptions and keep on top of the shifting story around Bodycote’s valuation.

Stay updated as the Fair Value for Bodycote shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bodycote.

???? Bullish Takeaways

Deutsche Bank analyst Thomas Elgar raised the price target on Bodycote to £8.60 from £7.00 with a Buy rating, signalling confidence that the company can execute on its strategy and support earnings growth beyond current market expectations.

The higher target from Deutsche Bank implies meaningful upside from recent trading levels. This suggests that, in the eyes of bullish analysts, medium term growth momentum and cost discipline are not yet fully reflected in the share price.

Even among more constructive voices, there is an acknowledgment that near term risks around demand and valuation remain. Upside is seen as increasingly dependent on consistent delivery against guidance and clear operational execution.

???? Bearish Takeaways

JPMorgan trimmed its price target to £6.00 from £6.10 and maintained a Neutral rating, underscoring a more cautious stance on Bodycote as near term demand uncertainty and execution risk weigh on conviction.

The modest cut in JPMorgan's target reinforces the idea that, for some analysts, much of the upside is already priced in. This also suggests that valuation leaves less room for error if growth or margins disappoint over the next few quarters.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Bodycote issued new earnings guidance for H2 2025–26, with management expecting stronger profit performance versus H1, underpinned by continued growth in Aerospace and Defence and better trading in Specialist Technologies.

The company anticipates H2 2025–26 operating profit to be ahead of H1 and broadly in line with H2 2024 levels, signalling confidence in sustaining recent profitability despite ongoing macro uncertainty.

Management highlighted increasing benefits from the Optimise programme as a key driver of margin expansion and efficiency gains, reinforcing the strategic focus on cost discipline and operational excellence.

Bodycote reaffirmed its commitment to the Optimise, Perform and Grow initiatives, positioning the group for a higher quality, more resilient and faster growing business model over the medium term.

Fair value has risen modestly from £7.44 to £7.78 per share, indicating a slightly higher central valuation estimate.

The discount rate has increased slightly from 8.55% to 9.01%, reflecting a marginally higher implied risk or required return.

Revenue growth has fallen significantly, shifting from a previously assumed 13.3% increase to a decline of approximately 8.4%, indicating a more cautious top line outlook.

Net profit margin has edged down from 15.71% to 15.13%, pointing to a small reduction in expected profitability levels.

The future P/E has risen from 13.9x to 15.4x, implying a higher assumed valuation multiple despite more conservative growth and margin forecasts.

Narratives are simple stories that connect your view of a company to the numbers, linking its business outlook to forecasts for revenue, earnings and margins, and then to a fair value. On Simply Wall St’s Community page, millions of investors use Narratives as an easy tool to compare Fair Value with the current price and decide when to buy or sell, with each Narrative updating dynamically as new news or earnings arrive.

Head over to the Simply Wall St Community and follow the Narrative on Bodycote to stay on top of:

How US aerospace and defence capacity expansions could drive mix improvement and margin resilience.

Whether Industry 4.0 Specialist Technologies and the Optimise programme can support a higher future P/E multiple.

How shrinking legacy markets and rising costs might challenge the path from today’s price to long term fair value.

Curious how numbers become stories that shape markets? Explore Community Narratives

Read the full Bodycote Narrative and track every update in real time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BOY.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com